Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

G Heller; R McCormack; T Kheoh; A Molina; MR Smith; R Dreicer; F Saad; Ronald de Wit; DT Aftab; M Hirmand; A Limon; K Fizazi; M Fleisher; JS de Bono; HI Scher

doi:10.1200/jco.2017.75.2998

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

G Heller, R McCormack, T Kheoh, A Molina, MR Smith, R Dreicer, F Saad, Ronald de Wit, DT Aftab, M Hirmand, A Limon, K Fizazi, M Fleisher, JS de Bono, HI Scher

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

147 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	572-+
Journal	Journal of Clinical Oncology
Volume	36
Issue number	6
DOIs	https://doi.org/10.1200/jco.2017.75.2998
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/jco.2017.75.2998

http://hdl.handle.net/1765/104777

Cite this

Heller, G., McCormack, R., Kheoh, T., Molina, A., Smith, MR., Dreicer, R., Saad, F., de Wit, R., Aftab, DT., Hirmand, M., Limon, A., Fizazi, K., Fleisher, M., de Bono, JS., & Scher, HI. (2018). Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. Journal of Clinical Oncology, 36(6), 572-+. https://doi.org/10.1200/jco.2017.75.2998

@article{666ccc8b46c749189ed7ec642e7956ea,

title = "Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials",

author = "G Heller and R McCormack and T Kheoh and A Molina and MR Smith and R Dreicer and F Saad and {de Wit}, Ronald and DT Aftab and M Hirmand and A Limon and K Fizazi and M Fleisher and {de Bono}, JS and HI Scher",

year = "2018",

doi = "10.1200/jco.2017.75.2998",

language = "Undefined/Unknown",

volume = "36",

pages = "572--+",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "6",

}

Heller, G, McCormack, R, Kheoh, T, Molina, A, Smith, MR, Dreicer, R, Saad, F, de Wit, R, Aftab, DT, Hirmand, M, Limon, A, Fizazi, K, Fleisher, M, de Bono, JS & Scher, HI 2018, 'Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials', Journal of Clinical Oncology, vol. 36, no. 6, pp. 572-+. https://doi.org/10.1200/jco.2017.75.2998

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. / Heller, G; McCormack, R; Kheoh, T et al.

In: Journal of Clinical Oncology, Vol. 36, No. 6, 2018, p. 572-+.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

AU - Heller, G

AU - McCormack, R

AU - Kheoh, T

AU - Molina, A

AU - Smith, MR

AU - Dreicer, R

AU - Saad, F

AU - de Wit, Ronald

AU - Aftab, DT

AU - Hirmand, M

AU - Limon, A

AU - Fizazi, K

AU - Fleisher, M

AU - de Bono, JS

AU - Scher, HI

PY - 2018

Y1 - 2018

U2 - 10.1200/jco.2017.75.2998

DO - 10.1200/jco.2017.75.2998

M3 - Article

SN - 0732-183X

VL - 36

SP - 572-+

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 6

ER -